- Home
- NKX vs PHAT Comparison
NKX vs PHAT Comparison
Compare NKX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- PHAT
- Stock Information
- Founded
- NKX 2002
- PHAT 2018
- Country
- NKX United States
- PHAT United States
- Employees
- NKX N/A
- PHAT N/A
- Industry
- NKX Finance/Investors Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- NKX Finance
- PHAT Health Care
- Exchange
- NKX Nasdaq
- PHAT Nasdaq
- Market Cap
- NKX 562.3M
- PHAT 640.9M
- IPO Year
- NKX N/A
- PHAT 2019
- Fundamental
- Price
- NKX $11.79
- PHAT $9.74
- Analyst Decision
- NKX
- PHAT Strong Buy
- Analyst Count
- NKX 0
- PHAT 5
- Target Price
- NKX N/A
- PHAT $16.40
- AVG Volume (30 Days)
- NKX 109.3K
- PHAT 1.0M
- Earning Date
- NKX 01-01-0001
- PHAT 08-07-2025
- Dividend Yield
- NKX 4.37%
- PHAT N/A
- EPS Growth
- NKX N/A
- PHAT N/A
- EPS
- NKX N/A
- PHAT N/A
- Revenue
- NKX N/A
- PHAT $114,039,000.00
- Revenue This Year
- NKX N/A
- PHAT $194.40
- Revenue Next Year
- NKX N/A
- PHAT $103.23
- P/E Ratio
- NKX N/A
- PHAT N/A
- Revenue Growth
- NKX N/A
- PHAT 1049.82
- 52 Week Low
- NKX $9.78
- PHAT $2.21
- 52 Week High
- NKX $12.00
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- NKX 63.04
- PHAT 61.57
- Support Level
- NKX $11.47
- PHAT $8.03
- Resistance Level
- NKX $11.85
- PHAT $10.09
- Average True Range (ATR)
- NKX 0.06
- PHAT 0.66
- MACD
- NKX 0.04
- PHAT 0.06
- Stochastic Oscillator
- NKX 84.21
- PHAT 85.89
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.